Urogen Pharma (NASDAQ:URGN) Cut to “Market Perform” at UBS

Urogen Pharma (NASDAQ:URGN) was downgraded by analysts at UBS from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, November 15th, The Fly reports.

URGN has been the topic of several other research reports. Jefferies Group increased their price objective on Urogen Pharma from $27.00 to $37.00 and gave the stock a “buy” rating in a research note on Monday, October 9th. Oppenheimer set a $51.00 target price on Urogen Pharma and gave the company an “outperform” rating in a research report on Tuesday, November 14th. Finally, Zacks Investment Research raised Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, October 18th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $36.80.

Shares of Urogen Pharma (NASDAQ:URGN) traded up $0.78 during trading hours on Wednesday, reaching $40.43. The company had a trading volume of 212,279 shares, compared to its average volume of 70,141. Urogen Pharma has a 52 week low of $13.01 and a 52 week high of $44.63.

In related news, major shareholder Proquest Investments Iv, L.P. sold 209,298 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was sold at an average price of $40.60, for a total value of $8,497,498.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Several large investors have recently bought and sold shares of URGN. FMR LLC acquired a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $13,892,000. Menora Mivtachim Holdings LTD. grew its position in shares of Urogen Pharma by 341.4% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 569,589 shares of the company’s stock valued at $17,953,000 after acquiring an additional 440,534 shares during the period. Hillhouse Capital Management Ltd. acquired a new stake in Urogen Pharma in the 2nd quarter worth about $6,363,000. Jennison Associates LLC acquired a new stake in Urogen Pharma in the 2nd quarter worth about $3,168,000. Finally, Wildcat Capital Management LLC acquired a new stake in Urogen Pharma in the 2nd quarter worth about $2,439,000. Hedge funds and other institutional investors own 34.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Urogen Pharma (NASDAQ:URGN) Cut to “Market Perform” at UBS” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/04/urogen-pharma-urgn-cut-to-market-perform-at-ubs-ag.html.

Urogen Pharma Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

The Fly

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply